Pfizer Announces U.S. FDA Approves XELJANZÂ tofacitinib for the Treatment of Moderately to Severely Active Ulcerative Colitis

XELJANZ an Oral Therapy is the First and Only JAK Inhibitor Approved in the U.S. for This Patient Population Pfizer Inc. NYSE PFE announced today that the United States U.S. Food and Drug Administration FDA approved XELJANZÂ ...